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A B S T R A C T
Objective: Adequate control of intractable epilepsy continues to be a challenge. Little is known about the
role of VNS therapy in intractable epilepsy in patientswho failed to respond to surgicalmanagement. The
objective of the present study is to determine the efﬁcacy of vagus nerve stimulation therapy in patients
with intractable epilepsy who have failed surgical and medical therapy.
Methods: All the patients who had persistent seizures after cranial surgery who subsequently
underwent vagus nerve stimulator (VNS) placement at our institution from 1998 to 2008 were included
in the study. Thirty-seven consecutive patients were enrolled and followed for the outcomemeasures of
seizure burden, anti-epileptic drug (AED) burden and quality of life (QoL). Minimum follow-up was 18
months.
Results: Overall, 24 (64.9%), 9 (24.3%), 4 (10.8%) patients reported less than 30%, between 30% and 60%
and greater than 60% reduction in seizure frequency after VNS placement, respectively at a mean of 5
years follow-up period. Post-VNS anti-epileptic requirement exhibited a decreasing trend. 17 patients
(45.9%) report an improvement in QoL (better or much better).
Conclusion: VNS therapy in patients who have failed medical and surgical therapies only provides
marginal improvement in seizure control but has greater likelihood to improve subjective QoL issues. In
addition, VNS has the potential to reduce AED burdenwithout adversely impacting seizuremanagement.
Given the low surgical risk of VNS placement, vagus nerve stimulation as a therapeutic modality should
be individualized to achieve best clinical response and fewest side effects.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Despite great advancement in surgery, localization techniques
and pharmacological therapies adequate control of intractable
epilepsy continues to be a challenge.1 Current surgical approach to
epilepsy relies heavily on localization of epileptogenic focus and
encompasses a diverse set of approaches that include partial focal
lobectomy, mesial temporal resection and corpus callosotomy
amongst others.2–5 Surgical treatment of intractable epilepsy can
provide long-term seizure reduction/control in 70–90% of
patients.6–9 Adequate seizure control remains a persistent problem
in patients who have failed initial surgical management.10–12* Corresponding author at: 2 Tampa General Circle, USF Health, 7th Floor,
Department of Neurosurgery, University of South Florida, Tampa, FL 33606, United
States.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.003Failure of surgery for epilepsy is multi-factorial with poor
predictability of which patients are destined to fail.8,13 Repeat
surgery has however shown to be less effective than the initial
attempt in addition to having increased surgical risk.12,13
Vagus nerve stimulator (VNS) is a FDA approved treatment
approach to refractory epilepsy.14 The VNS is an implantable
device for peripheral stimulation of the vagus nerve in the neck.
Though the exact mechanism of action is not fully elucidated, it is
believed that it can provide seizure control via a retrograde global
inhibitory effect on the central nervous system particularly
through the thalamus.15,16 Retrograde afferent stimulation of both
the thalamus and other midbrain/limbic structures, as a relay to
cortical modulation has been studied.17,18 The modulation of both
cortical electrical activity and possibly norepinephrine can
effectively reduce seizures in select patients.15,19 VNS has been
shown to be efﬁcacious in focal, generalized and syndromic forms
of epilepsy (i.e. Lennox-Gastaut).16,20,21 Historically it has served as
a treatment option for patients withmedically intractable epilepsy
who are not surgical candidates. There are few studies on efﬁcacyvier Ltd. All rights reserved.
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the efﬁcacy of vagus nerve stimulation in patients who continue to
have intractable seizures after epilepsy surgery.
2. Methods
2.1. Patient selection
A prospective data registry was established in 1998 for all
patients referred to our comprehensive epilepsy center for surgical
evaluation. 37 consecutive patients with drug-resistant epilepsy
who had unsatisfactory results from cranial surgery (lobectomy or
corpus callosotomy) and subsequently underwent VNS placement
at our institution between 1998 and 2008 were identiﬁed. Initial
patient selection for surgery was based on phase I localization of
epileptogenic foci, which consisted of video EEG and neuroimaging
(MRI and in some cases PET/SPECT). If surface EEG and imaging
were inconclusive then the patient underwent phase II localization
that consisted of cortical grid/strips or depth electrode placement
and video monitoring.
The patients who failed to respond to surgery were deemed
nonsurgical candidates for repeat surgery if re-localization did not
ﬁnd an appropriate resectable focus. Modiﬁed Engel classiﬁcation
scale was used to determine and stratify surgical failures.22 Engel
class III (worthwhile seizure reduction) and class IV (no
worthwhile improvement) outcomes were considered for VNS
placement and enrollment in the present study. A total of 37
patients were enrolled in this study with a minimum follow up of
one year (range: 18 months to 10 yrs). Demographic data are
displayed in Table 1.
During the ﬁrst few weeks after VNS implantation, the patients
were seen in the clinic to conﬁrmwound healing and assess proper
pulse generator operation. Stimulationwas started at a low current
setting (0.25 mA) and the current was increased gradually to allow
accommodation to the stimulation. For patient comfort, the output
current was increased in 0.25 mA increments until a comfortable
level was reached. Treatment parameters were individualized to
achieve the best clinical response with the fewest side-effects. InTable 1
Patient population statistics.
No. patients 37
Age at VNS placement
Mean 29.1
Median 27.4
Range 4.8–63.3 yrs
Range of follow up 18–127 months
Mean 61.7 months
Sex
Male (%) 46%
Female (%) 54%
Type of surgery (*6 patients had
two different surgical sites)
Temporal 24
Frontal 12
Occipital 1
Corpus callosotomy 6
No. of AEDs pre-implantation (%)
1 (2.7%)
2 (35%)
3 (46%)
4 (13.5%)
5 (2.7%)
No. of AEDs post-implantation (%)
at most recent follow-up
1 (13.5%)
2 (32.4%)
3 (24.3%)
4 (27%)
5 (2.7%)addition, AEDs remained stable for the ﬁrst three months of
stimulation to assess clinical response.
2.2. Outcomes
Outcomes were measured via a questionnaire at the most
recent scheduled follow up. Pre and post-operativemanagement of
anti-epileptic drugs was deferred to the patient’s treating
neurologist. Outcomes measured included seizure burden, AED
burden and quality of life (QoL).
Seizure burden (% seizure reduction) was subjectively quanti-
ﬁed as <30% reduction, 30–60% reduction and >60% reduction.
Pre-VNS anti-epileptic drug burden was compared to the number
of drugs the patient required at the most recent follow up. Finally,
QoL was investigated via ordinal analysis where the patient or
caregiver categorized his/her QoL as ‘‘much worst, worst, no
change, better or much better’’ as compared to post-cranial/pre-
VNS surgery.
3. Results
Individualization of treatment was the accepted treatment
modality. Output current was adjusted as necessary. Mean current
therapywas 2.5 mA (range: 1.5–3.0 mA) for the cohort. There were
no major complications noted in this group of patients (such as
infections or permanent vocal cord paralysis). Two patients
complained of transient persistent hoarseness on activation of
VNS. No patient was lost to follow-up. Patients and caregivers did
report an increase in efﬁcacy in the ﬁrst year after implantation,
but no signiﬁcant clinical changeswere noted after longer than one
year follow-up period.
Retrospective analysis of the 37 patients whomet the inclusion
criteria of Engel class III/IV was performed. Outcome measures
were analyzed individually as well as in combination via non-
parametric analysis (Mann–Whitney U). In regards to seizure
burden 24 (64.9%), 9 (24.3%), 4 (10.8%) patients reported less than
30%, between 30% and 60% and greater than 60% reduction in
seizure frequency after VNS placement as compared to post
craniotomy, respectively (Fig. 1). No patient was seizure-free
following VNS in this cohort. The reported percent seizure
reduction was determined by the patient/caregiver at the most
recent follow up (18 months to 10 yrs post VNS placement).
Poly-pharmacy was encountered in 94.5% of our post-surgical
patients with an Engel class III/IV outcome. Antiepileptic drug
requirement prior to VNS placement was from 1 to 5 medications.
35%, 46% and 13.5% of patients were on 2, 3 or 4 anti-epileptic
drugs with 2.7% (1/37) on either one or ﬁve at the time of
preoperative evaluation. Post-VNS anti-epileptic requirement
exhibited a decreasing trend with 13.5%, 32.4% and 24.3% of
patients requiring 1, 2 and 3 AEDs, respectively (Fig. 2). Patients
requiring only one AED increased frompre-VNS 2.7% to 13.5% post-
VNS. However, 11 of 37 (29.7%) of patient required at least 4 or 5
AEDs as compared to 6 patients (16.2%) pre-VNS. Non-parametric
analysis suggests that patients that reported less than 30%
reduction were more likely to be on 3 or more AEDs as compared
to those who reported between a 30-60% reduction (Mann–
Whitney U, p = 0.032). No patient was on VNS monotherapy.
Qualify of life, a quantiﬁcation of satisfaction, as reported by the
patient or caregiver underwent non-parametric analysis with both
AED requirement and seizure burden. QoL analysis demonstrated
that 19/37 (51.3%) of the patients had no change in self-reported
quality of life. No one reported getting ‘‘much worse’’ though one
patient did report being worse off. 17 patients (45.9%) report an
improvement in QoL (better or much better) (Fig. 3). Mann–
Whitney U analysis did not suggest any individual signiﬁcant
correlation when comparing QoL to AED or seizure burden.
[()TD$FIG]
Fig. 1. Seizure burden.
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tions (FR) (n = 31) versus corpus collosotomy (CC) (n = 6) was also
performed. There was no statistical difference between groups in
terms of pre and post-VNS placement number of AEDs. However,
>60% seizure reduction was only seen in the FR: 4/31 (13%).
Between 30 and 60% seizure reductionwas seen in 7/31 (23%) vs 2/
6 (33%) in the FR and CC groups, respectively. QoL analysis
demonstrated that 15/31 (48%) patients reported an improvement
(better or much better) for the FR group versus 2/6 (33%) for CC
patients. Furthermore, no signiﬁcant difference in the stimulation
parameters between groups was identiﬁed.
4. Discussion
Surgical management of intractable epilepsy is too often
reserved as a last line of treatment particularly in patients who
have failed medical management and who have a resectable lesion
or epileptogenic zone.23 Inevitably a certain subset of these
patients will fail surgical treatment. This subset of patients is the
most difﬁcult to treat and exhibit a form of epilepsy that is
refractory to conventional measures. Hence, in Engel class III/IV
epileptics, other avenues of treatments need to be considered
including but not limited to neuro-stimulation. Little is know
about the efﬁcacy of vagus nerve stimulation in this population of
epileptic patients.
Few studies have investigated VNS in post surgical patients.
Amar et al.24 reported the ﬁndings from a subgroup analysis of a
national registry data. They report a 45.7% and 50.5% median
reduction in seizure frequency after 12 and 24 months, respec-
tively. Their analysis of QoL (alertness, verbal communication,
memory, school/professional achievement, mood, postictal state
and seizure clustering) suggests a trend towards improvement
overtime, though statistical signiﬁcance was present only for
greater alertness. As they note, the data in the national registryrepresents a nonconsecutive cohort that is susceptible to reporting
and selection bias. This analysis of pre-marketing open label
registry concluded that VNS therapy is a potential option for
treatment of surgically failed intractable epilepsy even though the
statistical signiﬁcance of trends in efﬁcacy over time cannot be
veriﬁed (nonconsecutive data). A subgroup analysis of an outcome
designed study by Ben-Menachem25 of 18 Swedish patients
showed decreased in seizure frequency in 6 patients (one with
tumor) with reduction rates ranging from 20% to 75%.
Conversely, Koutroumanidis et al.26 analysis of 16 post surgical
patients suggests a limited efﬁcacy in seizure burden after vagus
stimulator placement. They report no change in 10 of the 16
patients (62.5%) in regards to both frequency and severity of
seizures in a similar fashion to our results. Only 3 patients had up
to a 50% reduction in frequency (18.75%). One patient’s seizures
had increased post VNS placement and hence had subsequently the
device removed. Interestingly, Koutroumanidis et al. results also
suggests positive psychotropic effect VNS in this patient popula-
tion. Three of their patient elected to keep their vagus nerve
stimulators for its positive psychotropic effect despite no change in
seizure burden. Other patients in their study exhibited decrease in
severity of psychosis and/or stabilization of mood.
Other clinical applications of VNS, which include major
depression, Alzheimer, migraines, eating disorder and mood
stabilization amongst others, have been investigated.27,28 The
positive psychotropic effects of VNS, particularly in regards to
resistant depression, have been a particular point of interest.29–32
Modulation of multiple neurotransmitters, neuro-modulators and
amino acids is a hypothesized mechanism of the positive
psychotropic side-effects of VNS.33 This positive psychotropic
effect of VNS must likely represent one of the many variables
involved in quality of life analysis in patients with VNS. As seen in
this study, subjective QoL determination was not associated with
any one variable alone. It represents a conglomeration of variables
[()TD$FIG]
Fig. 2. AED requirement.
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mood amongst others.
In our experience, patients who pre-VNS implantation required
more AEDs are more likely to have poorer outcomes than those
who are on fewer AEDs. Patients that reported less than 30%
reductionweremore likely to be on 3 ormore AEDs and only 10.8%
patients reported a >60% reduction in seizure burden. Quality of
life analysis does not directly correlate with seizure burden.[()TD$FIG]
Fig. 3. QualitIn regards to QoL, there is an approximate 50/50 split in regards
to improvement vs. no improvement (45.9% vs 51.3%). QOL is
multifactorial and may involve not only seizure burden but also
medication burden amongst other psychosocial factors as sug-
gested above. Subgroup analysis of patients who report ‘‘no
change’’/‘‘got worse’’ in QoL versus those who report an improve-
ment shows no signiﬁcant inter-group difference either pre-VNS
(p = 0.326) or post-VNS (p = 0.125). In regards to medicationy of life.
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placement was seen in this group of patients as previously
suggested in a case-controlled study.34 Study design and patient
selection may explain this ﬁnding.
When compared to national registry data our study suggest
only a marginal improvement in seizure burden with VNS post
cranial surgery. Approximately 65% of patient will have a less than
30% reduction in seizure frequency (Fig. 1). The true efﬁcacy of VNS
in intractable failed surgical epilepsy is unclear and controversial
in current literature. Studies report a wide range of percent seizure
reductions.24,26,35 Based on our experience, VNS therapy in
patients who have failed medical and surgical therapies only
provides marginal improvement in seizure control but greater
likelihood to improve subjective quality of life. These ﬁndingswere
independent of the type of intra-cranial procedure performed.
We acknowledge the limitations of a single center study and
therefore recommend further studies to corroborate our clinical
ﬁndings. In addition, this study includes a relatively small number
of patients in the analysis, but due to severity of the disease, may
still represent an accurate representation of this group of epileptic
patients.
5. Conclusion
VNS therapy inpatientswhohave failed surgical therapy seem to
provide marginal improvement in seizure control but has greater
likelihood to improve subjective quality of life. Further prospective
studies to elucidate the true efﬁcacyofVNS in epilepsy patientswith
apost-operativeEngel class III/IVoutcomeareneeded.Given the low
surgical risk of VNS placement, its use as a therapeutic modality in
intractable epilepsy should be left to the discretion of the surgeon
and epileptologist with the potential beneﬁt of drug reduction and
improvement quality of life kept in mind.
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